You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 雲頂新耀漲5% PTX-COVID19-B已獲准納入WHO新冠疫苗團結試驗計劃
格隆匯 12-21 15:08
格隆匯12月21日丨雲頂新耀(1952.HK)盤中漲5.75%,報39.5港元,總市值117億港元。12月20日, 雲頂新耀與Providence Therapeutics(“Providence”)共同宣佈,其mRNA新冠候選疫苗PTX-COVID19-B已在一獨立諮詢小組推薦下加入世界衞生組織(WHO)的新冠疫苗團結試驗(Solidarity Trial Vaccines)。PTX-COVID19-B是一種脂質納米顆粒mRNA疫苗,顯示了很強的免疫原性和耐受性,有潛力成為同類領先產品。WHO疫苗團結試驗是一項國際範圍內的隨機臨牀試驗計劃,旨在快速評估具有潛力的新候選疫苗的有效性和安全性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account